screen_shot_2013-02-11_at_11

Teva appoints Arie Belldegrun to Board of directors

pharmafile | February 11, 2013 | Appointment | Manufacturing and Production, Research and Development, Sales and Marketing Arie Belldegrun, Teva 

Teva Pharmaceuticals has announced that Dr Arie Belldegrun has been appointed by the directors of Teva to fill a vacancy on the Board.

“We are pleased to welcome Dr Belldegrun to our Board. Arie’s extensive experience in the pharmaceutical industry both as a doctor, a business leader and an academic will enable him to make significant contributions to the Board immediately and help guide us as we look for new and innovative ways to bring medicines to patients around the world and continue to increase value for our shareholders,” said Phillip Frost, chairman of the Board at Teva.

Belldegrun is a director of the UCLA Institute of Urologic Oncology and Professor and chair of Urologic Oncology at the David Geffen School of Medicine at the University of California, Los Angeles. Belldegrun also serves as the chairman of the Board of Kite Pharma, Arno Therapeutics, and TheraCoat Ltd.

Advertisement

Belldegrun received his medical degree at the Hadassah Medical School of the Hebrew University and conducted his post-doctoral studies at the Weizmann Institute of Science in Israel. He completed his residency in urologic surgery at Harvard Medical School and his surgical oncology fellowship at the National Cancer Institute (NCI) / National Institute of Health (NIH).

Related Content

Teva announces positive results from trial of AJOVY for migraine

Teva has announced positive results from the phase 4 PEARL study of AJOVY (fremanezumab), its …

louis-reed-pwckf7l4-no-unsplash_5

Sanofi and Teva partner for development of inflammatory bowel disease treatment

Sanofi and Teva Pharmaceuticals have announced that they will collaborate for the co-development and co-commercialisation …

judge-gavel-1461966002dbr

Teva’s cancer drug Bendeka protected from generics until 2031, judge rules

A US federal judge has ruled that generic versions of the cancer treatment Bendeka infringe …

The Gateway to Local Adoption Series

Latest content